These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28484728)

  • 1. Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients.
    Zharinov GM; Bogomolov OA; Neklasova NN; Anisimov VN
    Oncoscience; 2017 Jan; 4(1-2):7-13. PubMed ID: 28484728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior.
    Hanks GE; Hanlon AL; Lee WR; Slivjak A; Schultheiss TE
    Int J Radiat Oncol Biol Phys; 1996 Feb; 34(3):549-53. PubMed ID: 8621277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer.
    Hanlon AL; Horwitz EM; Hanks GE; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):43-52. PubMed ID: 14697419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
    Spurgeon SE; Mongoue-Tchokote S; Collins L; Priest R; Hsieh YC; Peters LM; Beer TM; Mori M; Garzotto M
    Urology; 2007 May; 69(5):931-5. PubMed ID: 17482937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of the prostate-specific antigen doubling time prior to and following radical prostatectomy to predict the outcome of prostate cancer.
    Takeuchi H; Ohori M; Tachibana M
    Mol Clin Oncol; 2017 Feb; 6(2):249-254. PubMed ID: 28357104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
    Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
    Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
    Semeniuk RC; Venner PM; North S
    Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.
    Pinover WH; Horwitz EM; Hanlon AL; Uzzo RG; Hanks GE
    Cancer; 2003 Feb; 97(4):1127-33. PubMed ID: 12569615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
    Lee WR; Hanks GE; Hanlon A
    J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Value of the Prostate-specific Antigen Doubling Time for the Effectiveness of Metastasis-directed Radiotherapy in Patients With Oligometastases After Radical Treatment for Non-metastatic Prostate Cancer.
    Koguchi D; Tabata KI; Hirano S; Shimura S; Satoh T; Ikeda M; Matsumoto K; Niibe Y; Iwamura M
    Cancer Diagn Progn; 2024; 4(5):638-645. PubMed ID: 39238621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
    BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer.
    Thomsen FB; Christensen IJ; Brasso K; Røder MA; Iversen P
    BJU Int; 2014 May; 113(5b):E98-105. PubMed ID: 24053601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
    Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
    Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.